Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 14,548 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 14,548 shares of Werewolf Therapeutics stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $1.05, for a total transaction of $15,275.40. Following the completion of the sale, the director directly owned 2,851,940 shares in the company, valued at $2,994,537. This trade represents a 0.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Luke Evnin also recently made the following trade(s):

• On Wednesday, December 17th, Luke Evnin sold 9,983 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total value of $11,380.62.
• On Monday, December 15th, Luke Evnin sold 23,640 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.07, for a total transaction of $25,294.80.
• On Friday, December 12th, Luke Evnin sold 17,858 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.08, for a total transaction of $19,286.64.
• On Thursday, December 11th, Luke Evnin sold 28,009 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.07, for a total value of $29,969.63.
• On Wednesday, December 10th, Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.06, for a total value of $39,330.24.
• On Tuesday, December 9th, Luke Evnin sold 44,570 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.01, for a total transaction of $45,015.70.
• On Monday, December 8th, Luke Evnin sold 34,041 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.99, for a total transaction of $33,700.59.
• On Friday, December 5th, Luke Evnin sold 16,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.97, for a total value of $16,070.96.
• On Thursday, December 4th, Luke Evnin sold 53,416 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.97, for a total value of $51,813.52.
• On Wednesday, December 3rd, Luke Evnin sold 36,726 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.87, for a total transaction of $31,951.62.

Werewolf Therapeutics Price Performance

NASDAQ:HOWL traded down $0.01 during midday trading on Wednesday, hitting $1.07. The company had a trading volume of 468,373 shares, compared to its average volume of 445,417. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. The company has a market capitalization of $51.94 million, a PE ratio of -0.66 and a beta of 0.74. The stock’s fifty day moving average price is $1.24 and its 200-day moving average price is $1.32. Werewolf Therapeutics, Inc. has a 52-week low of $0.60 and a 52-week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. As a group, research analysts expect that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Wall Street Analyst Weigh In

HOWL has been the topic of several analyst reports. Zacks Research downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Bank of America dropped their target price on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. JMP Securities lowered their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research note on Thursday, August 21st. Finally, Citigroup reissued a “market outperform” rating on shares of Werewolf Therapeutics in a research note on Wednesday, November 12th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Werewolf Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $7.75.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of large investors have recently added to or reduced their stakes in HOWL. Charles Schwab Investment Management Inc. grew its holdings in shares of Werewolf Therapeutics by 33.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock worth $93,000 after acquiring an additional 23,852 shares during the period. Nuveen LLC purchased a new stake in Werewolf Therapeutics in the 1st quarter worth approximately $71,000. MPM Asset Management LLC increased its stake in shares of Werewolf Therapeutics by 0.6% in the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock worth $4,189,000 after purchasing an additional 25,688 shares in the last quarter. MPM Bioimpact LLC increased its stake in Werewolf Therapeutics by 0.9% in the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock worth $2,341,000 after buying an additional 20,799 shares in the last quarter. Finally, AQR Capital Management LLC bought a new stake in Werewolf Therapeutics during the 1st quarter valued at approximately $79,000. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.